BioArctic AB

BIOA B

Equity

ISIN SE0010323311 / Valor 38514501

NASDAQ Nordic Exchange Stockholm, Equities (2024-09-18)

SEK 170.30+0.59%

BioArctic AB
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

BioArctic AB is a Swedish research-oriented biopharmaceutical company focused on developing new treatments for neurodegenerative disorders. With a diverse project portfolio at various stages of development, the company aims to improve the health of patients and create value for stakeholders. BioArctic's cutting-edge expertise in this area makes it an attractive partner for collaborations and investments in the biopharmaceutical industry.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

BioArctic AB reported net revenues of SEK 11 million for the fourth quarter of 2023, a significant increase from SEK 2 million in the same period the previous year. For the full year, net revenues reached SEK 616 million, up from SEK 228 million in 2022.

Operating Profit

The company achieved an operating profit of SEK 253 million for the full year of 2023, compared to a negative SEK 17 million in 2022. However, the fourth quarter saw an operating loss of SEK 78 million, up from a loss of SEK 60 million in Q4 2022.

Cash Flow

BioArctic AB's operating cash flow was a positive SEK 117 million in the fourth quarter of 2023, compared to a negative SEK 58 million in the same quarter the previous year. For the full year, operating cash flow was SEK 299 million, up from a negative SEK 32 million in 2022.

Net Result

The net result for the fourth quarter of 2023 was a negative SEK 87 million, compared to a negative SEK 58 million in Q4 2022. For the full year, the net profit was SEK 229 million, a significant improvement from a negative SEK 11 million in 2022.

Cash Balance

At the end of the fourth quarter of 2023, BioArctic AB's cash balance, including short-term investments, amounted to SEK 1,112 million. This strong financial position provides a solid foundation for future growth and investment.

Summarized from source with an LLMView Source

Key figures

-42.3%1Y

22.7%3Y

174%5Y

Performance

48.2%1Y

81.1%3Y

71.5%5Y

Volatility